ONCOLYTICS BIOTECH INC (ONCY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q1 '25: -5M Q2 '25: -4.7M Q1 '26: -9.3M Q2 '26: -9.4M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Net Income Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q1 '25: -4.7M Q2 '25: -5.3M Q1 '26: -9.2M Q2 '26: -9.4M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q1 '25: -4.7M Q2 '25: -4.1M Q1 '26: -7.3M Q2 '26: -8.1M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q1 '25: -4.7M Q2 '25: -4.1M Q1 '26: -7.3M Q2 '26: -8.1M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '25: 84.6M Q2 '25: 91M Q1 '26: 112.3M Q2 '26: 119.7M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.